Francisco Cortes-Benitez

Dr. Francisco Cortes-Benitez

Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RDRaphaël Dutour
Raphaël Dutour
JRJenny Roy
Jenny Roy
Francisco Cortes-BenitezFrancisco Cortes-Benitez
Francisco Cortes-Benitez
RMRené Maltais
René Maltais
DPDonald Poirier
Donald Poirier

20 July 2021 in Molecules
Verified
Journal Article
Open access
PDF file
LCLedy De la Cruz
Ledy De la Cruz
CDConstanza Duran-Becerra
Constanza Duran-Becerra
Martín González-AndradeMartín González-Andrade
Martín González-Andrade
JFJosé Carlos Páez Franco
José Carlos Páez Franco
Juan Manuel Germán-AcacioJuan Manuel Germán-Acacio
Juan Manuel Germán-Acacio
Francisco Cortes-BenitezFrancisco Cortes-Benitez
Francisco Cortes-Benitez
Regulating insulin and leptin levels using a protein tyrosine phosphatase 1B (PTP1B) inhibitor is an attractive strategy to treat diabetes and obesity. Glycyrrhetinic acid (GA), a triterpenoid, may weakly inhibit this enzyme. Nonetheless, semisynthetic derivatives of GA have not been developed as PTP1B inhibitors to date. Herein we describe the synthesis and evaluation of two series of indole- and N-phenylpyrazole-GA derivatives (4a–f and 5a–f). We measured their inhibitory activity and enzyme kinetics against PTP1B using p-nitrophenylphosphate (pNPP) assay. GA derivatives bearing substituted indoles or N-phenylpyrazoles fused to their A-ring showed a 50% inhibitory concentration for PTP1B in a range from 2.5 to 10.1 µM. The trifluoromethyl derivative of indole-GA (4f) exhibited non-competitive inhibition of PTP1B as well as higher potency (IC50 = 2.5 µM) than that of positive controls ursolic acid (IC50 = 5.6 µM), claramine (IC50 = 13.7 µM) and suramin (IC50 = 4.1 µM). Finally, docking and molecular dynamics simulations provided the theoretical basis for the favorable activity of the designed compounds.

8 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
KRKaren Rodríguez-Villar
Karen Rodríguez-Villar
LYLilián Yepéz-Mulia
Lilián Yepéz-Mulia
MCMiguel Cortés-Gines
Miguel Cortés-Gines
JPJacobo Aguilera Perdomo
Jacobo Aguilera Perdomo
EQEdgar A. Quintana-Salazar
Edgar A. Quintana-Salazar
Jaime Pérez-VillanuevaJaime Pérez-Villanueva
Jaime Pérez-Villanueva
Indazole is an important scaffold in medicinal chemistry. At present, the progress on synthetic methodologies has allowed the preparation of several new indazole derivatives with interesting pharmacological properties. Particularly, the antiprotozoal activity of indazole derivatives have been recently reported. Herein, a series of 22 indazole derivatives was synthesized and studied as antiprotozoals. The 2-phenyl-2H-indazole scaffold was accessed by a one-pot procedure, which includes a combination of ultrasound synthesis under neat conditions as well as Cadogan’s cyclization. Moreover, some compounds were derivatized to have an appropriate set to provide structure-activity relationships (SAR) information. Whereas the antiprotozoal activity of six of these compounds against E. histolytica, G. intestinalis, and T. vaginalis had been previously reported, the activity of the additional 16 compounds was evaluated against these same protozoa. The biological assays revealed structural features that favor the antiprotozoal activity against the three protozoans tested, e.g., electron withdrawing groups at the 2-phenyl ring. It is important to mention that the indazole derivatives possess strong antiprotozoal activity and are also characterized by a continuous SAR.

19 October 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RDRaphaël Dutour
Raphaël Dutour
Francisco Cortes-BenitezFrancisco Cortes-Benitez
Francisco Cortes-Benitez
JRJenny Roy
Jenny Roy
DPDonald Poirier
Donald Poirier

1 October 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MGMariana Garrido
Mariana Garrido
MCMarisa Cabeza
Marisa Cabeza
Francisco Cortes-BenitezFrancisco Cortes-Benitez
Francisco Cortes-Benitez
JGJosé Gutiérrez
José Gutiérrez
EBEugene Bratoeff
Eugene Bratoeff

24 February 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KRKaren Rodríguez-Villar
Karen Rodríguez-Villar
AHAlicia Hernández-Campos
Alicia Hernández-Campos
LYLilián Yepéz-Mulia
Lilián Yepéz-Mulia
TSTeresita Sainz-Espuñes
Teresita Sainz-Espuñes
OSOlivia Soria-Arteche
Olivia Soria-Arteche
Jaime Pérez-VillanuevaJaime Pérez-Villanueva
Jaime Pérez-Villanueva
Candidiasis, caused by yeasts of the genus Candida, is the second cause of superficial and mucosal infections and the fourth cause of bloodstream infections. Although some antifungal drugs to treat candidiasis are available, resistant strains to current therapies are emerging. Therefore, the search for new candicidal compounds is certainly a priority. In this regard, a series of indazole and pyrazole derivatives were designed in this work, employing bioisosteric replacement, homologation, and molecular simplification as new anticandidal agents. Compounds were synthesized and evaluated against C. albicans, C. glabrata, and C. tropicalis strains. The series of 3-phenyl-1H-indazole moiety (10a–i) demonstrated to have the best broad anticandidal activity. Particularly, compound 10g, with N,N-diethylcarboxamide substituent, was the most active against C. albicans and both miconazole susceptible and resistant C. glabrata species. Therefore, the 3-phenyl-1H-indazole scaffold represents an opportunity for the development of new anticandidal agents with a new chemotype.